Alphatec Spine Releases Alphatec NEXoss(TM) Nanostructure Bio-Active Matrix And Announces The First Patient Implant

CARLSBAD, Calif., Sept. 18, 2012 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today the first clinical use of Alphatec NEXoss, a next generation synthetic bone graft indicated for use in posterolateral spine fusions in conjunction with bone marrow aspirate, autograft bone and appropriate hardware.

Alphatec NEXoss is composed of two unique patented technologies. The first is an engineered extracellular collagen bioscaffold that provides a physical structure for cell infiltration and attachment. The second is osteoconductive nano-structured bone crystals that have similar composition, structure and size as human bone. These two technologies function together to provide an ideal environment for a natural bone growth solution. Alphatec NEXoss is supported by in vitro and in vivo clinical data.

Last month, Alphatec announced the acquisition of exclusive U.S. distribution rights to market the product under its own brand name called Alphatec NEXoss. Alphatec NEXoss is FDA-cleared for commercial sale.

The three-level posterior lumbar fusion procedure was performed by Joseph Stern, M.D., a neurosurgeon in private practice in Greensboro, NC. The patient was treated for progressive worsening of spondylolisthesis of L3-4 and L5-S1 with spinal stenosis and degenerative changes at L3-4, L4-5, and L5-S1 levels.

Dr. Stern chose Alphatec NEXoss as the fusion graft material based on the proven safety and effectiveness of the product technology. "I am very pleased with the excellent handling properties of Alphatec NEXoss," said Dr. Stern. The mixing and delivery system has been designed with the surgeon in mind and provides a very easy and effective way to deliver the graft both in open and MIS cases."

"Alphatec NEXoss is an excellent product and an important addition that strengthens our biologics portfolio with a synthetic bone matrix offering," said Les Cross, Alphatec Spine's Chairman and Chief Executive Officer. "What makes NEXoss effective is that its patented structure is nearly identical in composition to natural human bone.

If you liked this article you might like

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine

Buy These 5 Stocks Now to Catch the Breakouts

Insider Trading Alert - CBG, RPTP And ATEC Traded By Insiders

Insider Trading Alert - CRM, ATEC And TTGT Traded By Insiders

Alphatec Holdings Inc. Stock Upgraded (ATEC)